Lege Artis Medicinae

[Introducing a new, personalized multistep cognitive behavioral therapy for obesity]

CZEGLÉDI Edit1

DECEMBER 10, 2019

Lege Artis Medicinae - 2019;29(12)

DOI: https://doi.org/10.33616/lam.29.056

[Two thirds of Hungary’s adult population live with excess weight. Obesity itself is a chronic disease that is a risk factor for many other chronic diseases, and therefore adequate treatment is of public health impor­tance. Although behavioral therapy is one of the evidence-based approaches to treating obesity, its long-term effectiveness is not well-established. That is why intensive work has been done over the past decades to furth­er develop behavioral therapy. A recent example of this is a multi-step treatment program that can be implemented in a number of settings of the health care system regardless of the excess weight and the presence of comorbid conditions of obesity. This treatment program is based on classical behavioral treatments and new cognitive-behavioral treatments of obesity and, in addition to the acquisition of long-term lifestyle-changing skills, contributes to the treatment of obesity through the development of a mind-set for long-term weight control. The purpose of this study is to present the program.]

AFFILIATIONS

  1. Semmelweis Egyetem, Magatartástudományi Intézet

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Praeeclampsia - 2019]

TAMÁS Péter, KOPPÁN Miklós

[Preeclampsia remains one of the most serious gestational diseases. Accumulating data support the opinion that the pathogenesis of preeclampsia (gestational hypertension + organ dysfunction) is not homogenous. The early-onset (onset of clinical phase before the 34th gestational week) type is a placental disease in which hypertension and organ dysfunctions are due to vasoconstriction and microthrombosis. The late-onset form is a maternal disease in which water retention - in connection with obesity - beyond the given vascular capacity may be an important progenitor of the clinical signs. These considerations should also influence the strategy of the treatment. ]

Lege Artis Medicinae

[The Nobel Prize in Medicine and Physiology 2019]

VARGA János

Lege Artis Medicinae

[Suppressing the Passion to Paint, or Basic Dilemmas of Female Existence – Peder Severin Krøyer and Marie Triepcke ]

GEREVICH József

Lege Artis Medicinae

[Letter to our Readers]

KAPÓCS Gábor

Lege Artis Medicinae

[The adverse effects of smoking on our respiratory system based on data of the Hungarian Public Health Screening 2010-2018 ]

KÉKES Ede, DAIKI Tenno, DANKOVICS Gergely, BARNA István

[The regular smoking with or without clinical symptoms causes structural changes in the lung tissue and this is reflected in res­pi­ratory function tests. During the last 9 years of Hungary's comprehesive health promotion screening (MÁESZ) between 2010 and 2018, spiro­metric examinations (PEF, FEV1, MEF25-75, FVC) were performed on 70822 women and 60187 men. We used the percentage of predictive values in the analysis to describe the deviation from normal. The carbon monoxide (eCO) content measurement of the exhaled air (in ppm) was performed on 24899 women and 22340 men. The COPD Evaluation Ques­tionnaire (CAT) was completed by 4166 wo­men and 3170 men. All four parameters of spirometry showed lower values for smokers in both sexes, but in men they were lower than in women. Ageing lowered significantly the values. The rate of changes from normal predictive values and the difference between smokers and non-smokers was the highest for MEF25-75 and FVC. The expiratory CO content (eCO) was significantly higher in smokers than in non-smokers in all age groups. In smokers, the incidence in percent of abnormal CAT score was significantly higher. Respiratory screening tests reveal the harmful effects of smoking, even without clinical symptoms, and indicate the risk of developing COPD.]

All articles in the issue

Related contents

Clinical Neuroscience

[Personalised epilepsy treatment]

ALTMANN Anna

[Epilepsy is one of the most common chronic neurological disease in childhood. Patients with epilepsy – even with so-called benign epilepsy – need medication for years. During this time, children go through a very big change, not only gaining weight and height, but also changing hormonal and metabolic processes. Maturation processes in different brain areas also take place at different rates depending on age. All of these should be considered when preparing a therapeutic plan. In everyday practice after the diagnosis of epilepsy, the applied drug is most often selected based on the shape and type of seizure. However, a number of other factors need to be considered when designing a therapeutic strategy: 1. efficacy (form of epilepsy, type of seizure), 2. age, gender, 3. pharmacological properties of the drug, 4. adverse drug reaction profile, 5. lifestyle (community), figure (skinny, corpulent, obese), 6. other comorbidities (nutrition, behavioral and learning problems, circulatory disorders, kidney or liver disease), 7. expected interactions with other drugs already used, 8. genetics, 9. other aspects (drug registration and prescription rules). The purpose of this article is to help to decide which antiepileptic drugs are expected to have the least side effects in a particular child with different comorbidities and which medications should be avoided if possible.]

Clinical Neuroscience

[Pharmacological and nonpharmacological treatment of insomnias with regard to sleep medicine]

FALUDI Béla, ROZGONYI Renáta

[Insomnia - one of the most prevalent sleep complain - has a great impact on the everyday life. Basically two different form of insomnia can be defined: the insomnia disorder and the co-morbid insomnias. To treat adequately determination of background pathology is essential, which is based on the help of Sleep Medicine Centers. According to the newest guidelines, the treatment of insomnia disorder is based on cognitive behavioural therapies followed by pharmaceutical intervention. In this review we provide the short description of cognitive behavioural therapies and basic principles of hypnotic drugs. Despite the availability of insomnia guidelines the huge variation of the insomnia medication can be seen in the daily practice. Due to the above mentioned reasons we summarize the good clinical practice of hypnotic drug administration for insomnia patients.]

Clinical Neuroscience

Positive airway pressure normalizes glucose metabolism in obstructive sleep apnea independent of diabetes and obesity

KABELOĞLU Vasfiye, SENEL Benbir Gulçin, KARADENIZ Derya

The relationship among obstructive sleep apnea syndrome (OSAS), type 2 diabetes mellitus (DM2) and obesity is very complex and multi-directional. Obesity and increased visceral fat are important perpetuating factors for DM2 in patients with OSAS. On the other hand, OSAS itself leads to obesity by causing both leptin and insulin resistance as a consequence of activation of the sympathetic nervous system. Risk for developing DM2 further increases in patients with OSAS and obesity. Data regarding effects of positive airway pressure (PAP) therapy, gold standard treatment for OSAS, on glycemic control were inconsistent due to variability in duration of and adherence to PAP therapy. In our cohort study we investigated effects of PAP treatment on glucose metabolism in normal-weighted non-diabetic OSAS patients, in obese non-diabetic OSAS patients, and in OSAS patients with DM2. We prospectively analyzed 67 patients diagnosed with OSAS and documented to be effectively treated with PAP therapy for three months. Apnea-hypopnea index was highest in the diabetic group, being significantly higher than in the normal-weighted group (p=0.021). Mean HOMA values were significantly higher in obese (p=0.002) and diabetic group (p=0.001) than normal-weighted group; the differences were still significant after PAP therapy. HbA1c levels were significantly higher in diabetic group compared to those in normal-weighted (p=0.012) and obese (p=0.001) groups. After PAP treatment, decrease in HbA1c levels were significant in normal-weighted (p=0.008), obese (p=0.034), and diabetic (p=0.011) groups. There was no correlation with the change in HbA1c levels and age (p=0.212), BMI (p=0.322), AHI (p=0.098) or oxygen levels (p=0.122). Our study showed that treatment of OSAS by PAP therapy offers beneficial effect on glucose metabolism, not only in diabetic patients, but also in obese and normal-weighted OSAS patients. Although data regarding overall effects of PAP therapy on glycemic control present contradictory results in the literature, it should be emphasized that duration and adherence to PAP therapy were main determinants for beneficial outcome of treatment.

Lege Artis Medicinae

[The possibilities of pharmacological treatment of obesity]

PADOS Gyula, SIMONYI Gábor, BEDROS J. Róbert

[There have been attempts to treat obesity with medicines for nearly 100 years, since the discovery of ephedrine. For decades amphetamine derivates and agents stimulating or inhibiting the release of noradrenaline and dopamine have been applied. However, most of theses drugs had to be gradually withdrawn, due to their adverse effects on the cardiovascular and central nervous system or their sympaticotonic effect. Dexfenfluramine (Isolipan), which was introduced in the 90s, did not have such side effects, but it turned out to potentially cause valvular heart disease. Finally, sibutramin (Reductil) was introduced, which again had to be withdrawn in 2010 due to its hypertensive and cardiovascular side effects. After all, we were left without any appetite-suppressant drugs. Orlistat therapy, (Xenical 120 mg, alli 60 mg - OTC), which inhibits the absorption of fat, can eliminate only 30% of the consumed food’s fat content, at the price of gastrointestinal side effects. The latest result of research carried out wordwide is that in 2012 the FDA approved commercial distribution of the selective 5HT2/c serotonin agonist lorcaserin (Belviq), which enhances satiety, in the USA. Unfortunately, in 2013 the EMEA temporarily postponed the lauch of this drug, until certain adverse effects are excluded. For diabetic patients, the GLP-1 agonist exenatid and the GLP-analog liraglutid, which can also reduce body weight, are available in the form of injections.]

Clinical Oncology

[Obesity and cancer]

VALTINYI Dorottya

[The role of obesity in the development of cancer is well-known from ages. However, these days we witness the explosion-like increase of obesity, globally, but mainly in the economically advanced population, and, which is even more alarming, among youngsters. The prognosis of the obesity-related cancer is rather poor, therefore, the prevention, including the screening, have outstanding importance. Unfortunately, the participation of the obes persons, especially obes women, in these programs is very low. The diagnostics and therapies should consider the special features of obesity, which are related to the magnitude, distribution, composition of fatty tissue connected to the changes in pharmacokinetics. Moreover, the problems might be complicated with obesity-associated non-tumorous severe diseases (e.g. cardiovascular, diabetes type 2).This review covers different aspects of obesity-cancer relationships, with an emphasis on everyday oncology.]